Zerodha (Trading Account)
FREE Equity Delivery and MF
Flat ₹20/trade Intra-day/F&O
Zerodha (Trading Account)
FREE Equity Delivery and MF
Flat ₹20/trade Intra-day/F&O
|
|
Incorporated in 1973, Ajanta Pharma is a multinational company based out of India engaged in the development, manufacturing, and marketing of pharmaceutical formulations.
In India, the company has a presence in high-growth specialty segments of cardiology, dermatology, ophthalmology, and pain management. Emerging markets are the major contributors to the company's branded generic business where they are present across Asia and Africa. Ajanta Pharma serves a wide range of therapeutic segments like Anti-Biotic, Anti-Malarial, Anti-Diabetic, Cardiology, Gynecology, Orthopedics, Pediatric, Respiratory & General Health products in this region.
The company's Institutional business comprises supplies to various government bodies in India and supplies of Anti-Malarial products under WHO-approved programs in Africa.
Ajanta Pharma's products are sold in over 30 countries and the company employs around 7,000 people worldwide. The company operates 7 manufacturing facilities in India, 2 of which have been successfully approved by the US FDA. The company's R&D center has a team of over 750 scientists.
| Issue Period | February 3, 2022 - February 16, 2022 |
| Security Name | Ajanta Pharma Limited |
| Issue Type | Tender Offer |
| Issue Size (Shares) | 1,120,000 |
| Issue Size (Amount) | ₹285.60 Crores |
| Buyback Price | ₹2550 per share |
| Face Value | ₹2 per share |
| Listing At | BSE, NSE |
| Record Date | January 14, 2022 |
| Offer Opens On | February 3, 2022 |
| Last Date for receipt of Tender Forms | February 16, 2022 |
| Offer Closes On * | February 16, 2022 |
| Finalisation of Buyback Acceptance | February 24, 2022 |
| Last Date for settlment of bids | February 25, 2022 |
| Last Date for Extinguishment of Shares | March 4, 2022 |
| Category | Entitlement Ratio of Buyback |
|---|---|
| Reserved Category for Small Shareholders | 30 Equity Shares out of every 151 shares held on the record date. |
| General Category for all other Eligible Shareholders | 1 Equity Shares out of every 91 shares held on the record date. |
| Particulars | For the year/period ended (Rs. in Crores) | ||
|---|---|---|---|
| 30-Sep-21 | 31-Mar-21 | 31-Mar-20 | |
| Total Income | 1,694.96 | 2,915.67 | 2,680.06 |
| Profit After Tax | 369.69 | 653.87 | 467.70 |
| Net Worth | 3,358.90 | 2,995.63 | 2,598.87 |
| Reserves and Surplus | 3,341.51 | 2,978.24 | 2,581.33 |
| Month | High Price | Low Price | Average Price |
|---|---|---|---|
| Nov-2021 | 2,239.10 | 2,015.80 | 2,136.74 |
| Oct-2021 | 2,366.30 | 2,053.65 | 2,213.24 |
| Sep-2021 | 2,340.00 | 2,112.70 | 2,199.31 |
| Month | High Price | Low Price | Average Price |
|---|---|---|---|
| Nov-2021 | 2,239.10 | 2,000.00 | 2,137.44 |
| Oct-2021 | 2,365.80 | 2,053.65 | 2,213.37 |
| Sep-2021 | 2,330.00 | 2,110.00 | 2,201.05 |
The Buyback aims to :
i) Distribute surplus funds to shareholders and thereby enhance their overall return.
ii) Improve financial ratios like Earnings per share (EPS), Return on assets (ROA) and Return on Equity (ROE).
7 3.0 Rating:  Vote Here ... |
Sorry, we couldn't find any reviews, please check back later.
Ajanta Pharma Limited
‘Ajanta House’, 98 Govt Industrial Area, Chark
Kandivli (West),
Mumbai - 400 067, Maharashtra, India
Phone: +91 22 6606 1000
Email: investorgrievance@ajantapharma.com
Website: http://www.ajantapharma.com/
Link Intime India Private Ltd
Link Intime India Private Ltd
C 101, 247 Park, L.B.S.Marg,
Vikhroli (West), Mumbai - 400083
Phone: +91-22-4918 6270
Email: ajantapharma.buyback2022@linkintime.co.in
Website: https://linkintime.co.in/initial_offer/public-issues.html
Lead Manager(s)
Registered Broker
The Ajanta Pharma Buyback opens on February 3, 2022, and closes on February 16, 2022.
The Ajanta Pharma Buyback last day to buy is not available as of now.
The Ajanta Pharma Buyback is a Tender Offer.
Ajanta Pharma Buyback Schedule
| Buyback Opening Date | February 3, 2022 |
| Buyback Closing Date | February 16, 2022 |
| Last Date for receipt of Tender Forms | February 16, 2022 |
| Finalisation of Buyback Acceptance | February 24, 2022 |
| Last Date for settlment of bids | February 25, 2022 |
| Last Date for Extinguishment of Shares | March 4, 2022 |
The Ajanta Pharma Buyback is being offered at Rs ₹2550 per share per equity share.
| Category | Entitlement Ratio of Buyback |
|---|---|
| Reserved Category for Small Shareholders | 30 Equity Shares out of every 151 shares held on the record date. |
| General Category for all other Eligible Shareholders | 1 Equity Shares out of every 91 shares held on the record date. |
The record date for the Ajanta Pharma Buyback is January 14, 2022.
The issue size of Ajanta Pharma Buyback is of 1,120,000 equity shares at ₹2550 per share aggregating upto ₹285.60 Crores.
The Buyback aims to :
i) Distribute surplus funds to shareholders and thereby enhance their overall return.
ii) Improve financial ratios like Earnings per share (EPS), Return on assets (ROA) and Return on Equity (ROE).
All the eligible Shareholders of the Company holding either Physical Shares or Demat Shares as on the Record Date can participate in the buyback offer through their Stock Broker.
The eligible shareholder holding the shares in Demat form needs to inform their broker the details of the Equity shares they wish to tender in the Buyback Offer. The shareholder needs to transfer the tendered shares to a Special account of the clearing corporation. The broker, in turn, would place an order on the stock exchange for the buyback.
The eligible shareholder holding the shares in physical form needs to approach their broker with original share certificates and supporting documents. Upon completion of document verification, the broker places an order on the stock exchange and submits the original share certificate and TRS to the registrar.
The tender form and TRS are optional in the case of Demat shares but mandatory in the case of physical shares.
The Ajanta Pharma Buyback offers an opportunity for the shareholders to exit their positions at a premium price. In case you stay invested you would have an increased percentage of shareholding in the company and improved earnings per share. Thus, one should understand the company fundamentals along with one's need, goals, and risk appetite to decide if one wants to stay invested or participate in the buyback offer.
1| Link|February 9, 2022 12:34:51 PM
1| Link|January 31, 2022 9:25:33 PM
1| Link|February 3, 2022 2:00:48 PM
1| Link|February 1, 2022 12:41:58 PM
1| Link|January 22, 2022 1:28:25 PM
1| Link|January 12, 2022 9:31:37 PM
1| Link|January 12, 2022 6:51:08 PM
1| Link|January 10, 2022 10:07:55 PM
1| Link|January 11, 2022 7:32:23 PM
1| Link|January 11, 2022 7:26:22 PM
FREE Intraday Trading (Eq, F&O)
Flat ₹20 Per Trade in F&O
|
|
The buy back amount is not credited into my account still for the Ajanta Pharma.
Can anyone provide details when will this happen.